Your browser doesn't support javascript.
loading
Correction to: Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.
Wrishko, Rebecca E; McCrea, Jacqueline B; Yee, Ka Lai; Liu, Wen; Panebianco, Deborah; Mangin, Eric; Chakravarthy, Manu; Martinez-Cantarin, Maria P; Kraft, Walter K.
Afiliação
  • Wrishko RE; Merck & Co., Inc., Kenilworth, NJ, USA.
  • McCrea JB; Merck & Co., Inc., Kenilworth, NJ, USA. jackie_mccrea@merck.com.
  • Yee KL; Merck & Co., Inc., Kenilworth, NJ, USA.
  • Liu W; Merck & Co., Inc., Kenilworth, NJ, USA.
  • Panebianco D; Merck & Co., Inc., Kenilworth, NJ, USA.
  • Mangin E; Merck & Co., Inc., Kenilworth, NJ, USA.
  • Chakravarthy M; Merck & Co., Inc., Kenilworth, NJ, USA.
  • Martinez-Cantarin MP; Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA.
  • Kraft WK; Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA.
Clin Drug Investig ; 39(5): 453-454, 2019 May.
Article em En | MEDLINE | ID: mdl-30895461
The original version of this article unfortunately contained a mistake.
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Clin Drug Investig Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Clin Drug Investig Ano de publicação: 2019 Tipo de documento: Article